Emo Capital Corp. (OTCBB:NUVI) Rebonces Off Bottom on New Promotions
Emo Capital Corp. (OTCBB:NUVI) is one of those strugglers that need a strong motivation to push off the bottom. And now a bargain price of about 2 cents arrived, leading to record buying. All the events of the past months are highly paradoxical, as NUVI seems unable to react even to well-developed email publicity campaigns. The ticker added more than 34% to $0.021, on dollar volumes above $328,000. 
Except- if the email is delivered just as NUVI is about to hit rock-bottom. The attention for this ticker happens for the first time since the summer months, and may create an interesting turn of events at the end of the year. The latest mail is from HoleinOneStocks.net. 
Yet NUVI enters a whole new story now, at a price of a few pennies. This time, even the sad balance sheet may be irrelevant, at least in the initial enthusiasm. NUVI holds:
- Zero cash and assets
- $33,850 total current liabilities
- $1,084 net loss
This is unfortunately too little for the upcoming creation and marketing of RED XL pill, a new formula in the market for male enhancement drugs. And despite the new website- which boasts with insignificant things such as design and fresh colors- NUVI does not hold much water.
The curious thing is that for NUVI, all the emails from a retinue of promoters come for an unknown compensation, probably even for free. At such a low price, this is a ticker that can boost records outright. The series of messages began in mid-November, but without impressive results, and little change in the generally weak volumes.
It is clear that NUVI is not a regular pharmaceutical company, but rather a vehicle for a risky venture in a risky industry.
But even hopeful companies from the pharmaceutical sector have bad days sometimes. Advanced Cell Technology, Inc. (OTCBB:ACTC) is one of the riskier bets, relying on still unproven stem cell research for its success. For now, ACTC survives, still stuck between 6 and 7 cents, awaiting a breakthrough or a deeper crash.
And while Biozone Pharmaveuticals, Inc. (OTCBB:BZNE) has almost everything going right, its stock is still regularly depressed by profit-taking, again fluctuating between 60 and 70 cents.
If you still believe NUVI holds potential this time, keep in mind that for this ticker, volumes are habitually weak. The company shows too many red flags, so it is best to invest affordable sums only and not get stuck with unsellable stocks.
